
    
      This is a multi-center, randomized, double-masked Phase 1/2a trial designed to evaluate the
      safety and tolerability of ALY688 Ophthalmic Solution in subjects with moderate to mildly
      severe dry eye for 8 weeks with 6 scheduled clinic visits.
    
  